Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) CEO Peter Greenleaf Sells 195,593 Shares

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) CEO Peter Greenleaf sold 195,593 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the completion of the sale, the chief executive officer now directly owns 1,953,892 shares of the company’s stock, valued at $15,631,136. This trade represents a 9.10 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Aurinia Pharmaceuticals Trading Up 1.3 %

NASDAQ:AUPH opened at $8.08 on Wednesday. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -53.86 and a beta of 1.22. Aurinia Pharmaceuticals Inc. has a one year low of $4.71 and a one year high of $10.67. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The business’s 50-day simple moving average is $8.13 and its 200 day simple moving average is $7.85.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of institutional investors have recently made changes to their positions in AUPH. Tang Capital Management LLC increased its stake in shares of Aurinia Pharmaceuticals by 16.6% in the fourth quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company’s stock worth $75,697,000 after buying an additional 1,200,000 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter worth about $9,662,000. Point72 Asset Management L.P. bought a new position in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $7,630,000. Lazard Asset Management LLC lifted its position in shares of Aurinia Pharmaceuticals by 341.9% during the fourth quarter. Lazard Asset Management LLC now owns 596,389 shares of the biotechnology company’s stock worth $5,355,000 after purchasing an additional 461,430 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Aurinia Pharmaceuticals in the third quarter worth about $3,330,000. 36.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 19th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.